A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

• Status: Terminated
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mati Therapeutics Inc.
• Treatments: Olopatadine Hydrochloride

Criteria

Inclusion Criteria:

• History of allergic conjunctivitis to ragweed for at least one year

• Positive skin prick test to ragweed pollen within 12 months prior to visit 1

• BCVA of at leat 20/400

Exclusion Criteria:

• Structural lid abnormalities (ectropion, entropion)

• Active lid disease ( ie moderate or severe blepharitis, meibomianitis) that requires medical treatment

• Presence of follicular conjunctivitis, anterior uveitis or preauricular lymphadenopathy

• History of ophthalmic abnormality, including a history of dry eye

• Perennial allergic rhinoconjunctivitis having significant allergy to animal dander that cannot be avoided during the study period

• History of chronic bacterial or viral ocular infection, such as herpes keratitis, and/or presence of active bacterial or viral ocular infection

• presence of mucous discharge, excess lacrimation or burning as a symptoms of ocular disease

• Currently on any chronic ocular topical medications

• Use of topical or systemic ocular medications during the study period

• History of complications, adverse events, trauma or disease in the nasolacrimal area

• History of symptomatic epiphoria